Summary & Overview
HCPCS J3101: Injection, Tenecteplase, 1 mg
HCPCS Level II code J3101 designates a 1 mg injection of tenecteplase, a thrombolytic agent used in acute care settings for reperfusion therapy. Nationally, accurate coding of thrombolytic drugs matters for clinical tracking, hospital billing, and pharmacy inventory control, and it influences how payers adjudicate high-cost injectable therapies. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J3101 represents clinically and operationally, along with payer coverage scope and typical sites of service. The publication outlines benchmark considerations for billing this drug, common modifier usage patterns provided in the input, and the clinical context for tenecteplase administration. It also highlights areas where policy updates or payer-specific edits commonly affect reimbursement and claims processing. This summary is intended to help coding, billing, and revenue cycle teams understand the code's role in acute thrombolytic therapy workflows and prepare for payer-specific requirements.
Billing Code Overview
HCPCS Level II code J3101 represents an injection of tenecteplase, 1 mg. This code is used to report the drug product administered by intravenous injection. The service type is medication administration for a thrombolytic agent, and the typical site of service is an acute care setting such as an emergency department or inpatient hospital where thrombolytic therapy is delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department or interventional cardiology suite with an acute ST-elevation myocardial infarction (STEMI) or a large acute pulmonary embolism when systemic thrombolysis is indicated and tenecteplase is selected. The patient has chest pain, shortness of breath, hypotension, or cardiogenic shock and has been evaluated with electrocardiography, cardiac biomarkers, and imaging as appropriate. After contraindications to fibrinolysis are reviewed and consent is obtained (when feasible), the pharmacist or nurse prepares J3101 (tenecteplase, 1 mg) for single bolus intravenous administration dosed by weight per institutional protocol. The clinical workflow includes medication reconciliation, verification of indications and contraindications, preparation of the dose, administration as a single IV bolus, monitoring for bleeding and reperfusion, documentation of lot number and amount administered, and post-administration observation in the ED, cath lab, or ICU. Typical sites of service include the emergency department, inpatient hospital units, intensive care unit, and cardiac catheterization laboratory.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no modifier applies to the claim for tenecteplase. |